SB-284851-BT is a chemical compound that serves as an inhibitor of BRD4, p38α, and BRDT, exhibiting varying degrees of affinity and inhibition for each. Specifically, it inhibits BRD4-BD1 with an IC50 value of 1.7 µM, p38α with a Kd of 0.47 nM, BRDT (1) with an IC50 value of 18 µM, and BRD4 (1) with an IC50 value of 3.7 µM. By targeting p38α, SB-284851-BT effectively reduces IL-8 production and, through inhibiting BRD4, down-regulates both the c-Myc and NF-κB gene pathways, crucial in cancer pathways. Additionally, SB-284851-BT is designed to combine with the bromine domain and extra terminal (BET) proteins.